Document Detail

Antiviral re-treatment of IFN-Ribavirin non-responders for recurrent post-transplantation hepatitis C.
MedLine Citation:
PMID:  20438578     Owner:  NLM     Status:  In-Data-Review    
Yedibela S, Demir R, Melling N, Aydin Ü, Schuppan D, Müller V, Hohenberger W, Schönleben F. Antiviral re-treatment of IFN-Ribavirin non-responders for recurrent post-transplantation hepatitis C. Clin Transplant 2011: 25: 131-135. © 2010 John Wiley & Sons A/S. Abstract: Background:  The aim of the study was to compare the efficacy and tolerability of pegylated interferon (PEG-IFN) plus ribavirin (RIB) and PEG-IFN monotherapy after unsuccessful initial therapy with interferon-α2b (IFN) plus RIB after recurrent post-transplantation hepatitis C. Methods:  Twenty-four patients with either no response (n = 10) or relapse (n = 14) after treatment with IFN plus RIB were prospectively randomized in the two treatment arms: 1) PEG-IFN monotherapy at a dosage of 0.8 μg/kg per week (n = 12) and 2) PEG-IFN (0.8 μg/kg per week) plus RIB (800-1200 mg/d) (n = 12). Results:  Twenty-one patients (86%) were treated for at least six months. Three patients are still being treated. At the end of therapy, 18 patients (75%) were HCV RNA negative. Five (45%) patients in PEG-IFN and five (50%) in PEG-IFN plus RIB arms had sustained virological response. Two patients (10%) died from recurrent hepatocellular carcinoma. The histologic activity indices significantly improved in both treatment arms. In the PEG-IFN arm, one patient experienced an acute rejection and discontinued therapy. Conclusions:  Both treatment arms showed to be effective, well tolerated and lead to an improvement in histologic outcome. Because of lower rates in side effects and equal outcome, PEG-IFN monotherapy is an adequate option for antiviral re-treatment.
Süleyman Yedibela; Resit Demir; Nathaniel Melling; Unal Aydin; Detlef Schuppan; Volker Müller; Werner Hohenberger; Frank Schönleben
Related Documents :
8844478 - A randomized, double-blind, controlled trial of natural interferon-beta therapy for e-a...
15134188 - No benefit to continue lamivudine therapy after emergence of ymdd mutations.
17713158 - Substitutions due to antiretroviral toxicity or contraindication in the first 3 years o...
10606318 - Impact of protease inhibitors on the outcome of human immunodeficiency virus-infected p...
8611088 - Long-term results of pylorus-preserving pancreatoduodenectomy for chronic pancreatitis.
25474558 - Doppler for growth restriction: the association between the cerebroplacental ratio and ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical transplantation     Volume:  25     ISSN:  1399-0012     ISO Abbreviation:  Clin Transplant     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-02-08     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8710240     Medline TA:  Clin Transplant     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  131-5     Citation Subset:  IM    
Copyright Information:
© 2010 John Wiley & Sons A/S.
Department of General Surgery, University of Erlangen-Nuremberg, Krankenhausstr, Erlangen, Germany Department of General Surgery, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey Beth Israel Deaconess Medical Center, Boston, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hypogammaglobulinemia and bronchiectasis in mycophenolate mofetil-treated renal transplant recipient...
Next Document:  Liver transplant from Anti-HBc-positive, HBsAg-negative donor into HBsAg-negative recipient: is it s...